Aligos Therapeutics, Inc.【ALGS】
時価総額
$617.6万
PER
小分子とオリゴの創薬を行うバイオ医薬の新興企業。ALG‑125755の第1相（20–200mg/50–320mg）でHBsAg低下を確認したHBV治療候補を展開。Merckとの共同研究に加え2023年5月にAmoytopから700万ドルの前受金を受領。米国・欧州を中心に展開。
| 2020年 12月31日 | 2021年 12月31日 | 2022年 12月31日 | 2023年 12月31日 | 2024年 12月31日 | |
| Revenue from collaborations | - | 4 | 14 | 9 | 0 |
| Revenue from customers | - | - | - | 6 | 4 |
| Research and development | 80 | 104 | 85 | 73 | 70 |
| General and administrative | 18 | 29 | 26 | 31 | 23 |
| Total operating expenses | 98 | 133 | 111 | 104 | 93 |
| Loss from operations | -98 | -128 | -98 | -88 | -89 |
| Interest and other income, net | -11 | 0 | 2 | 1 | 4 |
| Change in fair value of common warrants | - | - | - | - | 46 |
| Loss before income tax | - | -128 | -96 | -87 | -131 |
| Income tax provision | 0 | 0 | 0 | 1 | 0 |
| Net loss | -109 | -128 | -96 | -88 | -131 |
| Unrealized gain on available-for-sale securities | - | - | - | 0 | 0 |
| Unrealized (loss) gain on pension plans | 0 | 1 | -0 | -0 | 0 |
| Other comprehensive (loss) income | - | - | - | 0 | -0 |
| Comprehensive loss | -109 | -128 | -96 | -88 | -131 |
| Net loss per share, basic | - | - | - | -1.36 | -20.94 |
| Net loss per share, diluted | - | - | - | -1.36 | -20.94 |